1.1Oxadiazole linker joins fragments
The fragments attach to carbon atoms 3 and 5 of the oxadiazole. The aromatic ring fixes the two attachment directions and provides hydrogen-bond acceptor sites.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The fragments attach to carbon atoms 3 and 5 of the oxadiazole. The aromatic ring fixes the two attachment directions and provides hydrogen-bond acceptor sites.
The phenyl ring attaches to the amide nitrogen through carbon 1 and carries OH at carbon 4. The hydroxyl group adds a hydrogen-bond donor and acceptor site at the outer edge of the ring.
An oxygen atom connects the scaffold to a terminal methyl group. The oxygen provides a hydrogen-bond acceptor and positions the methyl group one bond beyond the scaffold attachment site.
The scaffold bonds directly to one carbon of a carbon–carbon triple bond, and the second carbon bears hydrogen. The triple bond holds the two carbons in a linear arrangement that projects from the attachment site.
The nitrogen bonds to the two neighboring ring atoms and contributes one electron to the aromatic π system. Its lone pair lies in the plane of the ring and provides a hydrogen-bond acceptor at B4.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A covered bait station houses a removable cellulose pad containing a formula I compound dispersed in a starch gel. The station sits at bench legs or floor junctions where monitoring indicates crawling arthropod activity. Side openings admit target arthropods, and the cover shields the pad from overhead irrigation.
An ester group, —C(═O)—O—, replaces the —C(═O)—N(R5)— linker while preserving the attachment positions on the flanking fragments. The carbonyl-bearing fragment provides the carboxylic acid component, and the opposite fragment provides the hydroxyl component for ester formation. Liquid chromatography measures hydrolysis during storage, and a separate contact assay measures activity against the target arthropod.
A 2,5-disubstituted 1,3,4-oxadiazole ring replaces the amide linker, with the two flanking fragments attached at the ring's carbon atoms. The corresponding diacylhydrazine carries one flanking fragment on each acyl group and undergoes cyclodehydration to form the ring. A concentration series in a leaf-disc assay measures arthropod mortality for the resulting compound.
A rotary seed coater applies an aqueous suspension of a formula I compound to three independent 1 kg seed batches at 0.1, 0.3, and 1.0 g of active ingredient per kilogram of seed. Each batch receives the same total liquid volume by adjusting the concentration of the active ingredient in the suspension. The coated batches dry separately, and seed subsamples are tested for loading uniformity and germination before pest exposure.
A transplanting machine carries a separate agitated tank containing an aqueous suspension of a formula I compound. A metering pump feeds a shielded nozzle mounted between the transplant placement mechanism and the closing wheels. A sensor at the placement mechanism triggers a single spray pulse onto the root plug and adjacent soil before the wheels close the planting slot.
Fixed cameras image sticky monitoring cards, and software counts target arthropods and associates each card with a greenhouse bench zone. The controller compares counts from successive images against a configured threshold for each zone. When the threshold is reached, the controller opens the valve for that zone and meters a spray suspension containing a formula I compound through its dedicated nozzle bank.
R5 is cyclopropyl, with one ring carbon bonded directly to the amide nitrogen. The attached carbon bears one hydrogen, and the other two ring carbons are methylene groups.
R1 is a one-carbon alkyl group with three fluorine substituents. The carbon bonds directly to the scaffold, and the three carbon–fluorine bonds make the group electron withdrawing.
R2 is a methyl group bearing a cyano substituent. The methylene carbon connects the scaffold to the nitrile carbon, and the terminal nitrile nitrogen acts as a hydrogen-bond acceptor.
B1 is a pyridine-type ring nitrogen bonded to its two neighboring ring atoms. The nitrogen contributes one electron to the aromatic π system, and its in-plane lone pair acts as a hydrogen-bond acceptor.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Ra is C1-6 alkyl, NR2R2, Rb is —H, —C1-6 alkyl, —COR3, —SO2R3, —SONR3R3, R5 is selected from —H, —C1-6 alkyl, —C3-6 cycloalkyl, —C1-6 alkylsubstituted alkyl, —C1-6 alkyl-NR8R9, —COR6, —COCOR6, —SO2R7 and —SO2NR2R2; with the proviso that only one of R4 or R5 can be selected from —COR6, —COCOR6, —SO2R7 and —SO2NR2R2;B · US 2019/0307776 A1 · claim 28
The phenyl group of the benzyl moiety could be optionally substituted by 1-3 moieties independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy and cyano. “Cx-C7” notation indicates a structural element comprised of carbons numbering between ‘x’ and ‘y’.B · US 2019/0307776 A1 · ¶ 73
Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated.A · US 2009/0099236 A1 · ¶ 83
Ra is: hydrogen; fluoro; or alkyl;A · US 2009/0099236 A1 · claim 28
Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated.A · US 2009/0099236 A1 · ¶ 83
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of theA · US 2009/0099236 A1 · ¶ 81
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of theA · US 2009/0099236 A1 · ¶ 81
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of theA · US 2009/0099236 A1 · ¶ 81
“Azaindole” means a group of the formula wherein one or two of any of X1, X2, X3 and X4 is N (aza), and the others are carbon. “Azaindoles” may be optionally substituted, as defined herein for heteroaryls, at position 1, 2 and 3, and at any of positions 4- through seven that are not nitrogen. “Azaindole” thus includes: “pyrrolopyrimidines” of the above formula wherein X2 and X4 are N; “pyrrolopyrimidines” of the above formula wherein X1 and X3 are N; “pyrrolopyrazines” of theA · US 2009/0099236 A1 · ¶ 81
R1 is: (a) aryl selected from phenyl and naphthyl, each optionally substituted; or (b) heteroaryl selected from indolyl, indazolyl, pyridinyl, thienyl, furanyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuranyl, benzothiophenyl or benzoxazinyl, each optionally substituted;A · US 2009/0099236 A1 · claim 28
Y is selected from —COOR2, —C(O)NR2SO2R3, —C(O)NHSO2NR2R2, —NR2SO2R2, —SO2NR2R2, —C3-6 cycloalkyl-COOR2, —C2-6 alkenyl-COOR2, —C2-6 alkynyl-COOR2, —C1-6 alkyl-COOR2, —NHC(O)(CH2)p—COOR2, —SO2NR2C(O)R2, -tetrazole, and —CONHOH, wherein p is 1-6; alternatively, Y is selected from a phenyl or heteroaryl ring, optionally further substituted with 1 to 3 substituents selected from —H, -halo, -hydroxyl, —C1-6 alkyl, —C1-6 alkoxy, —COOR2, —CN, —NO2, —CF3, —SO2, —NR26R27, —CONR26R27,B · US 2019/0307776 A1 · ¶ 13
An empty cell means only that no passage was reproduced there.
In particular, compounds of the present invention are useful for treatment of diseases associated with monoamine reuptake inhibitors.A · US 2009/0099236 A1 · ¶ 2
Dual reuptake inhibitors of serotonin and norepinephrine also offer potential treatments for disorders and disease states of the urinary tract, and for pain and inflammation.A · US 2009/0099236 A1 · ¶ 4
Despite the armamentarium of agents and drug combinations, there remains a medical need for new anti-retroviral agents, due in part to the need for chronic dosing to combat infection.B · US 2019/0307776 A1 · ¶ 4
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions, and their use in inhibiting HIV and treating those infected with HIV or AIDS.B · US 2019/0307776 A1 · ¶ 7
patent.fyi, US 2026/0354380 A1, claim 1, first published 2026-11-18T21:55:14-05:00, https://patent.fyi/US20260354380/, SHA-256 42c82998f82210cd10f94278af5f8848278f519813580081e6991c70b2d8cd9a